

**CAEBV International Symposium Program Draft as of Jan 30, 2026**

Venue: Yushima Campus, Institute of Science Tokyo

\* Topics and titles of the presentations are to be confirmed

**\*\* The session name "Panel Discussion" on March 21 is changed to "Workshop"**

Thursday, March 19, 2026		
18:00	<b>Welcome Reception</b> (for international guests only)	TBD
Friday, March 20, 2026		
9:15-9:30	<b>President's Opening Remarks</b>  Ayako Arai, St. Marianna University School of Medicine, Japan	Lecture Room "Kyoyo 1"
9:30-12:00  18min presentations x 7 speakers	<b>Education Session</b>  Chair:  Taizo Wada, Kanazawa University  Speakers:  Ayako Arai, St. Marianna University School of Medicine, Japan <i>Pathophysiology</i>  Benjamin Fournier, INSERM, Imagine Institute, France <i>Diagnosis</i>  Tomoko Miyake, Okayama University, Japan <i>Cutaneous CAEBV</i>  Kohei Yamamoto, Chicago University/ USA, Institute of Science Tokyo, Japan <i>Pathology</i>  Akihisa Sawada, Osaka Women's and Children's Hospital, Japan <i>Treatment</i>  Aika Fuseya, St. Marianna University School of Medicine, Japan <i>Prognostic Factors</i>  Nader El-Mallawany, Baylor College of Medicine, USA <i>EBV-HLH</i>	Lecture Room "Kyoyo 1"

12:00-12:50	<b>Luncheon Seminar</b> Sponsored by Chugai Pharmaceutical Co., Ltd.  Chair:  Masahide Yamamoto, Institute of Science Tokyo, Japan  Speaker:  Shinichi Makita, National Cancer Center, Japan <i>Additional Indication of Tecentriq</i>	Lecture Room “Kyoyo 1”
12:50-13:10	Coffee Break	
13:10-14:25  10 min presentations x 6 speakers  2 min for each presentation to answer questions from the audience	<b>Virology Session</b>  Chair:  Atsushi Kaneda, Chiba University, Japan  Speakers:  Hiroshi Kitamura, Tohoku Medical and Pharmaceutical University, Japan <i>EBV Genome and EBV, Geographical Characteristics and Disease Specificity</i>  Yoshitaka Sato, Nagoya University, Japan <i>Genomic alterations of EBV in human malignancies</i>  Shuntaro Isogai, Chiba University, Japan <i>Virus–chromatin interactions and chromatin activation</i>  Satoru Kondo, Kanazawa University, Japan <i>Is EBV-positive Neoplasm Really Latent Infection?</i>  Claudia Cabezas, Universidad de Concepción, Chile <i>HTLV Infection in Chile</i>  Ana-Maria Tutu, Carol Davila University of Medicine and Pharmacy, Romania <i>HTLV Infection in Romania</i>	Lecture Room “Kyoyo 1”
14:30-15:20	<b>Invitation Lecture</b>	Lecture

	<p>Chair:</p> <p>Toshiki Watanabe, St. Marianna University School of Medicine, Japan</p> <p>Jun-ichiro Yasunaga, Kumamoto University, Japan <i>Pathophysiology and Clinical Aspects of ATL</i></p> <p>Makoto Nakajima, St. Marianna University School of Medicine, Japan <i>Pathophysiology and Clinical Aspects of HAM</i></p>	Room “Kyoyo 1”
15:20-15:40	Coffee Break	
<p>15:40-17:30</p> <p>10 min presentations x 9 speakers</p> <p>2 min for each presentation to answer questions from the audience</p>	<p><b>The Latest Research on the Pathogenesis Mechanism and the Treatment of CAEBV</b></p> <p>Chair:</p> <p>Yoji Sasahara, Tohoku University, Japan</p> <p>Hiroaki Miyoshi, Kurume University, Japan</p> <p>Speakers:</p> <p>Miwako Nishio, Institute of Science Tokyo <i>Pathophysiological Analysis Using Patient-derived iPS Cells</i></p> <p>Ho Guiyi, The National University Cancer Institute, Singapore <i>Spatial Analysis of Disease Lesions</i></p> <p>Yu Uemura, St. Marianna University School of Medicine, Japan <i>Cytokine Profiling and Immune Signatures</i></p> <p>Antoine Gonde, INSERM, Imagine Institute, France <i>Genetic Background Underlying Disease Onset</i></p> <p>Claire Shannon-Lowe, University of Birmingham, UK <i>Role of Myeloid-Derived Suppressor Cells (MDSCs)</i></p> <p>Ryo Akazawa, Kyoto University, Japan <i>Genomic and epigenomic analysis</i></p> <p>Seok Jin Kim, Samsung Medical Center, South Korea <i>Disease Mechanisms and Therapeutic Strategies</i></p>	Lecture Room “Kyoyo 1”

	<p>Ai Kotani, Osaka University, Japan <i>Anti-Transferrin Receptor Antibody Therapy</i></p> <p>Miki Ando, Juntendo University, Japan <i>Cytotoxic T Lymphocyte (CTL)-Based Therapy</i></p>	
17:30–17:45	Break	
17:45-18:45	<p><b>Case Study Discussion</b></p> <p>Chair: Hiroshi Yasui, St. Marianna University School of Medicine, Japan</p> <p>Speakers:</p> <p>Ayako Arai, St. Marianna University School of Medicine, Japan <i>Introduction to CAEBV</i></p> <p>Ayuri Ishikawa, St. Marianna University School of Medicine, Japan <i>Is HSCT Necessary in the case of EBV-HLH of Primary Infection and Without Immunodeficiency?</i></p> <p>Case 2 TBD</p>	Lecture Room “Kyoyo 1”
19:00-20:30	<b>Networking Reception</b>	Faculty Lounge
Saturday, March 21, 2026		
<p>9:00-11:00</p> <p>Topic 1 7 mins x 8 panelists</p>	<p><b>Workshop</b></p> <p>Chair:</p> <p>Ayako Arai, St. Marianna University School of Medicine, Japan</p> <p><b>Topic 1</b> <b>Global Registry System</b> <b>CAEBV Today in each Country</b></p> <p>Presenters:</p> <p>Hiroshi Yasui, St. Marianna University School of Medicine, Japan</p> <p>Hyery Kim, Asan Medical Center, South Korea</p>	Lecture Room “Kyoyo 1”

	<p>David Boutboul, INSERM, Imagine Institute, France</p> <p>Claire Shannon-Lowe, University of Birmingham, UK</p> <p>Federico Erbella, University Vita-Salute San Raffaele, Italy</p> <p>Bianca Constantin, National Institute Fundeni, Romania</p> <p>Macarena Roa, Universidad de Chile, Chile</p> <p>Qingluan Yang, Huashan Hospital, Fudan University, China</p> <p>Nader El-Mallawany, Baylor College of Medicine, USA</p> <p><b>Topic 2</b> <b>International CAEBV Consortium</b></p>	
11:00-11:15	Coffee Break	
11:15-12:25  10 min presentations x 5 speakers  2 min for each presentation to answer questions from the audience	<p><b>Latest Research on Pathophysiology and Treatment</b></p> <p>Chair:</p> <p>Akihisa Sawada, Osaka Women's and Children's Hospital, Japan</p> <p>Speakers:</p> <p>Subaru Wakisaka, St. Marianna University School of Medicine, Japan <i>Analysis of Registry Data</i></p> <p>Eichi Kodama, Tohoku University, Japan <i>New Therapeutic Drugs for EBV</i></p> <p>TBD, Institute of Science Tokyo, Japan <i>ASO for EBV</i></p> <p>Hisashi Iizasa, Shimane University, Japan <i>Will EBV-derived Micro RNA be a Therapeutic Target?</i></p> <p>David Boutboul, INSERM, Imagine Institute, France <i>CAEBV Treatment in France</i></p>	Lecture Room "Kyoyo 1"
12:25-13:15	<p><b>Luncheon Seminar</b></p> <p>Sponsored by LSI Medience Corporation</p>	Lecture Room "Kyoyo"

	<p>Chair:</p> <p>Hiroshi Yasui, St. Marianna University School of Medicine, Japan</p> <p>Speaker:</p> <p>Hirokazu Kanegane, Institute of Science Tokyo, Japan</p>	1”
13:15-13:30	Coffee Break	
13:30-14:00	<b>Networking Event with Patients 1</b>	Faculty Lounge
14:00-15:30	<p><b>Networking Event with Patients 2A</b></p> <p>Speakers:</p> <p>Hiroshi Yasui, St. Marianna University School of Medicine, Japan <i>Diagnosis of CAEBV</i></p> <p>Masahide Yamamoto, Institute of Science Tokyo, Japan <i>Treatment of CAEBV</i></p> <p>SHAKE, Japan <i>CAEBV Patient Advocate Activities</i></p> <p>Guests:</p> <p>General participants</p>	Lecture Room “Kyoyo 1”
14:00-15:30	<p><b>Networking Event with Patients 2B by invitation only</b></p> <p>All symposium speakers</p> <p>General participants by invitation</p>	Faculty Lounge
15:30-15:40	<p><b>President’s Closing Remarks</b></p> <p>Ayako Arai, St. Marianna University School of Medicine, Japan</p>	Lecture Room “Kyoyo 1”